Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIA: Candesartan Dose Finding in Non-diabetic Nephropathy
NCT00573430Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2007
- Primary completion
- Aug 2009
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of candesartan cilexetil in Non-diabetic nephropathy and hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in Urinary Protein/Creatinine Ratio at 28 weeks. Started Dec 2007; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
Non-diabetic nephropathyhypertension (HTN)
Beyond the preview
Go deeper on NCT00573430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573430.